Mersana Therapeutics
9 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) (NCT05329545) | Mersana Therapeutics | 2022-06-23 |
| Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer (NCT04907968) | Mersana Therapeutics | 2021-06-11 |
| First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b (NCT04396340) | Mersana Therapeutics | 2020-05-11 |
| First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b (NCT06517485) | Mersana Therapeutics | 2019-07-30 |
| First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b (NCT06517433) | Mersana Therapeutics | 2017-12-12 |
| First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b (NCT03319628) | Mersana Therapeutics | 2017-12-12 |
Track Mersana Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.